Human leukocyte interferon (IF) was found active in homologous human and heterologous rodent cells both in antiviral tests and in tests measuring cell-growth inhibitory activity. About 10 times more units of human IF were required for a 50% inhibition of multiplication of the sensitive LB2 subline of mouse L cells than for a comparable inhibition of these cells by homologous mouse IF. The BHK-21 line of hamster kidney cells and the CSV-21 subline of mouse L cells proved insensitive toward the cell-growth inhibitory action of human interferon, although both lines were sensitive toward it’s antiviral effect. An analysis of fractions obtained in PAGE of human IF indicates two types of profiles in human cells. One of them corresponds to the profile of IF observed in mouse or hamster cells. The results indicate that the antiviral and the cell-growth inhibitory effects of interferon, in both homologous and heterologous cells, are greatly influenced by the species of animal cells used for tests.

Keywords:
Interferon, human, Cell-growth inhibition by interferon, Electrophoretic profiles of interferon, Antiviral activity of interferon
This content is only available via PDF.
© 1974 S. Karger AG, Basel
1974
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.